Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04615403 | Study of Exchange of Travoprost Intraocular Implant | PHASE2 | COMPLETED | 33 | — | — | Nov 19, 2020 | Feb 28, 2022 | Sep 26, 2023 | 14 | United States, Philippines |
Number of subjects with Adverse Events including intra-operative and post-operative events (TEAE's) in the study eye
| Arm | Type | Description |
|---|---|---|
| Implantation and Exchange | EXPERIMENTAL | Subjects will undergo implantation and exchange of a Travoprost Intraocular Implant through a small temporal clear corneal incision. |
| Name | Type | Description |
|---|---|---|
| Travoprost | DRUG | Implantation and exchange of a Travoprost Intraocular Implant through a clear corneal incision |
Inclusion Criteria: * Able and willing to attend scheduled follow-up exams for the duration of the study * Able and willing to provide written informed consent on the IRB (institutional review board)/IEC (institutional ethics committee)-approved Informed Consent form * Best spectacle corrected visu...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 3 | PHASE4 | Travoprost Intraocular |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE4 | Test - Bimatoprost 0.01%, Reference - LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE4 | Bimatoprost |
| United Therapeutics Corporation | UTHR | 1 | PHASE4 | Nicotinomide |
| Alcon AG | ALC | 3 | PHASE4 | Undisclosed |